Загрузка...
A Phase I and Pharmacologic Study of the Combination of Bortezomib and Pegylated Liposomal Doxorubicin in Patients with Refractory Solid Tumors
PURPOSE: Pre-clinical studies combining the proteasome inhibitor bortezomib with anthracyclines have shown enhanced anti-tumor activity. We therefore conducted a phase I trial of bortezomib and pegylated liposomal doxorubicin (PLD) in patients with refractory solid tumors. METHODS: Patients received...
Сохранить в:
| Опубликовано в: : | Cancer Chemother Pharmacol |
|---|---|
| Главные авторы: | , , , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
2008
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4312589/ https://ncbi.nlm.nih.gov/pubmed/18327587 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-008-0716-8 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|